ImmuCell(US:ICCC) Globenewswireยท2025-11-13 21:05Core Insights - ImmuCell Corporation reported a significant turnaround in financial performance for the nine-month period ended September 30, 2025, achieving a net income of $1.8 million compared to a net loss of $2.7 million in the same period last year, driven by higher product sales and improved gross margins [4][9]. Product Sales Highlights - Preliminary product sales for Q3 2025 were approximately $5.5 million, reflecting an 8% decrease compared to Q3 2024 [8]. - For the nine-month period ended September 30, 2025, product sales increased by 7% to approximately $20.0 million compared to the same period in 2024 [8]. - Over the twelve-month period ended September 30, 2025, product sales rose by 16% to approximately $27.8 million compared to the previous year [8]. Financial Performance - Gross margin improved to 43% for Q3 2025, up from 26% in Q3 2024, and reached 42.6% for the nine-month period ended September 30, 2025, compared to 27.3% in 2024 [5][9]. - The net loss for Q3 2025 was approximately $140,000, or $0.02 per basic share, compared to a net loss of $702,000, or $0.09 per basic share, in Q3 2024 [9][14]. - Adjusted EBITDA for Q3 2025 was approximately $751,000, significantly up from $196,000 in Q3 2024 [9][17]. Balance Sheet Data - As of September 30, 2025, cash and cash equivalents increased to approximately $3.9 million from $3.8 million as of December 31, 2024 [9][16]. - Net working capital rose to approximately $12.8 million as of September 30, 2025, compared to $10.6 million at the end of 2024 [9][16]. - Stockholders' equity increased to approximately $29.8 million as of September 30, 2025, up from $27.5 million as of December 31, 2024 [10][16]. Product Development - The company is actively developing Re-Tain, a treatment for subclinical mastitis in dairy cows, in partnership with Michigan State University, with ongoing market feedback collection planned through 2025 and into 2026 [6][20].